http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2015, Vol. 24 ›› Issue (11): 701-711.DOI: 10.5246/jcps.2015.11.090

• 【综 述】 •    下一篇

GLP-1的N端修饰研究进展及其用于治疗II型糖尿病的应用前景

白晓辉1, 牛有红1, 熊德彩1, 吴艳芬1*, 李云森2*   

  1. 1. 北京大学医学部 天然药物及仿生药物国家重点实验室, 北京 100191
    2. 苏州沪云肿瘤研究中心有限公司, 江苏 苏州 215123
  • 收稿日期:2015-05-18 修回日期:2015-07-28 出版日期:2015-11-20 发布日期:2015-08-15
  • 通讯作者: Tel.: 86-10-82801558, E-mail: wuyanfen@pku.edu.cn, yunsenli@suda.edu.cn
  • 基金资助:
    Beijing Natural Science Foundation (Grant No. 7152085).

Advances of N-terminal modifications of GLP-1 and their applications for the treatment of type 2 diabetes

Xiaohui Bai1, Youhong Niu1, Decai Xiong1, Yanfen Wu1*, Yunsen Li2*   

  1. 1. State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
    2. Suzhou Pharmavan Cancer Research Center Co., Ltd, Suzhou 215123, China
  • Received:2015-05-18 Revised:2015-07-28 Online:2015-11-20 Published:2015-08-15
  • Contact: Tel.: 86-10-82801558, E-mail: wuyanfen@pku.edu.cn, yunsenli@suda.edu.cn
  • Supported by:
    Beijing Natural Science Foundation (Grant No. 7152085).

摘要:

胰高血糖素样肽-1(GLP-1)是一种人体内源性的肠促胰素, 具有极强的体内降血糖活性,但在血浆中易被二肽基肽酶IV(DPP-IV)迅速降解失活, 由于DPP-IV的酶切位点靠近GLP-1N, 因此对N端进行结构修饰, 可以延长GLP-1的体内降血糖活性。过去有关GLP-1N端修饰研究中, 主要包括对His7Ala8Glu9的结构修饰以及一些其他的结构改造(包括GLP-1的缩短肽类似物、小分子受体激动剂等), 以期望在增强对DPP-IV酶降解耐受能力的同时, 保持较好的受体结合力与激动活性。至今为止, 用甘氨酸(Gly)或者α-氨基异丁酸(Aib)取代GLP-1NAla8修饰策略已被用于II型糖尿病药物(ExenatideSemaglutideAlbiglutideTaspoglutide)的临床研究中。本文具体描述已经报道的各类GLP-1N端修饰研究工作进展, 并讨论其在II型糖尿病治疗药物研发中的应用前景。

关键词: GLP-1类似物, DPP-IV, N端修饰, II型糖尿病

Abstract:

Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic hormone with excellent blood glucose-lowering activity, however, it is rapidly inactivated in the plasma mainly by dipeptidyl peptidase IV (DPP-IV). To overcome this problem, various N-terminal modifications of GLP-1 have been performed to prolong the in vivo biological activity,by improving the DPP-IV resistance while retaining receptor affinity and receptor activation. These studies have included modifications of His7, Ala8 or Glu9 at the N-terminus of GLP-1 and some other modifications. Among them, Ala8 substitutions with glycine (Gly8) and α-aminoisobutyric acid (Aib8) have been clinically applied in the development of diabetic therapy, such as Exenatide, Semaglutide, Albiglutide and Taspoglutide. In this review, we introduce N-terminal modifications of GLP-1 that have been reported, and discuss their potential and challenges for the treatment of type 2 diabetes.

Key words: GLP-1 analogues, DPP-IV, N-terminal modification, Type 2 diabetes

中图分类号: 

Supporting: